GDF-11
GDF-11 (Growth Differentiation Factor 11) is a member of the TGF-beta superfamily that gained prominence from parabiosis rejuvenation studies, with demonstrated effects on cardiac hypertrophy, neurogenesis, and skeletal muscle, though its role in aging remains highly controversial.
GDF-11 (Growth Differentiation Factor 11), also known as BMP-11, is a secreted protein belonging to the transforming growth factor-beta (TGF-beta) superfamily. It gained worldwide attention in 2013-2014 when Harvard researchers reported that GDF-11 was a circulating factor in young blood responsible for reversing age-related cardiac hypertrophy, restoring neurogenesis, and improving skeletal muscle function in aged mice through heterochronic parabiosis.
Overview
GDF-11 was originally characterized in the late 1990s as a developmental patterning factor essential for anterior-posterior axis specification, kidney morphogenesis, and neuronal differentiation. GDF-11 knockout mice die within 24 hours of birth due to renal agenesis, cleft palate, and skeletal abnormalities including extra vertebrae and ribs. In adults, GDF-11 signals through activin type II receptors (ActRIIA and ActRIIB) and type I receptors (ALK4 and ALK5), activating the Smad2/3 intracellular cascade.
The 2013-2014 parabiosis publications from the Wagers and Lee laboratories at Harvard electrified the aging field by identifying GDF-11 as a rejuvenating blood factor that declines with age. However, subsequent work by Egerman et al. (2015) at the Novartis Institutes and others demonstrated that the commercial GDF-11 assays used in the original studies cross-reacted with GDF-8/myostatin (90% sequence homology in the mature domain), that recombinant GDF-11 causes muscle wasting rather than regeneration, and that GDF-11 levels may actually increase with age. The controversy highlights the challenges of studying closely related TGF-beta superfamily members with nearly identical receptor usage.
Despite the controversy, GDF-11 remains an important molecule in developmental biology, hematopoiesis, and potentially aging research. The cardiac and neurogenic findings have been more consistently replicated than the muscle findings, and the clinical success of ActRIIB-Fc ligand traps (sotatercept, luspatercept) validates the therapeutic relevance of the GDF-11/activin signaling axis.
Mechanism of Action
GDF-11 signals through the canonical TGF-beta/activin pathway:
Receptor Binding: GDF-11 mature homodimer binds to activin type II receptors (ActRIIA and ActRIIB) with high affinity (Kd ~0.1-0.5 nM for ActRIIB). This recruits and phosphorylates type I receptors ALK4 (ActRIB) or ALK5 (TbetaRI). The receptor binding profile is nearly identical to that of GDF-8/myostatin, explaining their overlapping biological activities. Sako et al. (2010) characterized the receptor binding specificities of multiple TGF-beta superfamily members.
Smad Signaling: Activated ALK4/ALK5 phosphorylates receptor-Smads (Smad2 and Smad3), which complex with the co-Smad (Smad4) and translocate to the nucleus to regulate target gene transcription. Key target genes include p21 (CDKN1A), PAI-1 (SERPINE1), and inhibitory Smads (Smad6/7) as negative feedback. Nakashima et al. (1999) originally characterized GDF-11's signaling through Smad2/3.
Prodomain Regulation: Like other TGF-beta superfamily members, GDF-11 is synthesized as a large precursor that is cleaved by furin-like proprotein convertases. The prodomain remains non-covalently associated with the mature dimer, maintaining it in a latent state. BMP-1/tolloid-like metalloproteinases cleave the prodomain to release active GDF-11, providing an additional layer of regulation. Ge et al. (2005) demonstrated that BMP-1/tolloid proteinases activate latent GDF-11.
Endogenous Inhibitors: GDF-11 is antagonized by follistatin, follistatin-like 3 (FSTL3), and GASP-1/2, which bind the mature dimer and prevent receptor engagement. This is functionally important because the same inhibitors also regulate myostatin, creating a complex regulatory network. Follistatin binds GDF-11 with Kd ~0.5-1 nM, effectively neutralizing its bioactivity. The ratio of free to inhibitor-bound GDF-11 likely determines tissue-level signaling output, and age-related changes in these inhibitor levels may contribute to altered GDF-11 signaling in aging.
Reconstitution Calculator
GDF-11
**GDF-11** (Growth Differentiation Factor 11), also known as BMP-11, is a secret
Exceeds syringe capacity
Dose requires 2.000mL but syringe holds 1mL. Increase BAC water, use a larger syringe, or split injections.
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Parabiosis and Cardiac Rejuvenation
The seminal study by Loffredo et al. (2013) in Cell reported that heterochronic parabiosis (surgical joining of old and young mice to share circulation) reversed age-related cardiac hypertrophy in old mice. Using an aptamer-based proteomic platform, they identified GDF-11 as a circulating factor that declines with age and whose restoration recapitulates the cardiac benefits of young blood. Recombinant GDF-11 administered to old mice reduced cardiomyocyte size and cardiac hypertrophy markers. This landmark study was published from the laboratory of Amy Wagers and Richard Lee at Harvard.
Neurogenesis
Katsimpardi et al. (2014) published in Science that GDF-11 supplementation in aged mice restored cerebral vasculature density, enhanced neurogenesis in the subventricular zone (SVZ), and improved olfactory function. Young blood exposure through parabiosis produced identical effects, and recombinant GDF-11 alone was sufficient to drive these neurogenic responses in aged animals, suggesting GDF-11 as a key mediator of young blood's brain-rejuvenating effects.
Embryonic Development
GDF-11 is essential for embryonic anterior-posterior patterning. McPherron et al. (1999) showed that GDF-11 knockout mice have homeotic transformations of the axial skeleton (anterior transformation of vertebrae, resulting in extra thoracic and lumbar vertebrae), renal agenesis, and absent tail. GDF-11 regulates Hox gene expression in the developing spinal cord and determines the rostrocaudal positioning of motor neuron columnar identity. This developmental role is distinct from GDF-8/myostatin, which primarily regulates muscle mass.
Pancreatic and Metabolic Effects
GDF-11 has emerging roles in metabolic regulation beyond the aging controversy. Harmon et al. (2004) demonstrated that GDF-11 regulates the number of islet progenitor cells during pancreatic development by promoting cell cycle exit through p27 upregulation. In adult metabolic models, GDF-11 has been reported to improve glucose tolerance and reduce adiposity in high-fat diet-fed mice, though these findings require replication with GDF-11-specific assays. The ActRIIB signaling axis also intersects with adipose tissue biology, as activin and GDF-11 signaling in adipocytes influences thermogenesis and brown fat differentiation.
GDF-11 vs GDF-8/Myostatin
The 89.9% sequence identity between mature GDF-11 and GDF-8 creates significant challenges for researchers. Both bind ActRIIB with similar affinity, both activate Smad2/3, and both are inhibited by follistatin. Key differences: GDF-11 is more broadly expressed (in brain, spleen, pancreas, kidney, skeletal muscle), while GDF-8 expression is largely restricted to skeletal muscle. Their roles in development are non-redundant — GDF-11 knockout causes skeletal patterning defects, while GDF-8 knockout causes muscle hypertrophy (the "mighty mouse" phenotype). Walker et al. (2016) provided a detailed comparison of GDF-11 and GDF-8 biology.
Hematopoiesis
GDF-11 also plays roles in erythropoiesis and hematopoietic stem cell regulation. Luspatercept (ActRIIB-Fc) was originally developed based on the observation that GDF-11 and activin signaling through ActRIIB restrains late-stage erythroid differentiation. Blocking this signaling with luspatercept promotes red blood cell maturation and has been FDA-approved for beta-thalassemia and myelodysplastic syndrome-associated anemia. Suragani et al. (2014) showed that ActRIIB ligand traps correct ineffective erythropoiesis by blocking GDF-11 and activin signaling in erythroid progenitors.
Skeletal Muscle — The Controversy
Sinha et al. (2014) reported in Science that GDF-11 restored muscle stem cell (satellite cell) function and improved muscle structure and strength in aged mice. However, this finding was directly challenged by Egerman et al. (2015) in Cell Metabolism, who demonstrated three critical problems: (1) the SomaLogic aptamer-based assay used to measure GDF-11 cross-reacted extensively with GDF-8/myostatin, (2) an immunoassay specific for GDF-11 showed that GDF-11 levels actually increase with age in both rats and humans, and (3) recombinant GDF-11 administration caused skeletal muscle atrophy and reduced satellite cell expansion, consistent with its known signaling through the myostatin/ActRIIB pathway.
Schafer et al. (2016) in Circulation Research further complicated the picture, showing that while both GDF-11 and GDF-8 decline in aged humans when measured by a GDF-11-specific assay, the biological effects of supraphysiological GDF-11 on muscle were inhibitory rather than regenerative. The GDF-11 debate remains unresolved, with differences potentially attributable to dosing, timing, assay specificity, and the difficulty of distinguishing GDF-11 from GDF-8 effects in vivo.
Safety Profile
GDF-11 has no established human safety profile, as no human clinical trials of GDF-11 itself have been conducted. Preclinical data provide the following considerations:
- Muscle wasting: Recombinant GDF-11 at doses used in rejuvenation studies (0.1 mg/kg/day) causes skeletal muscle atrophy in some studies (PMID: 26456508), consistent with myostatin-like activity
- Developmental toxicity: GDF-11 is a potent morphogen; any clinical application would need to exclude pregnant individuals
- Dose sensitivity: TGF-beta superfamily members commonly exhibit narrow therapeutic windows with biphasic dose-response curves
- Off-target Smad2/3 activation: Chronic Smad2/3 signaling promotes fibrosis in liver, kidney, and lung; supraphysiological GDF-11 could theoretically exacerbate organ fibrosis
- Cancer considerations: TGF-beta/activin pathway activation has context-dependent roles in cancer — tumor suppressive early, pro-metastatic late. Long-term GDF-11 effects on tumor biology are unknown
- Assay limitations: Difficulty distinguishing GDF-11 from GDF-8 effects in vivo means that some reported safety signals may reflect GDF-8 (myostatin) activity rather than true GDF-11 effects
Pharmacokinetic Profile
- Half-life
- Minutes to hours (circulating, exact value not established)
- Metabolism
- Clearance involves receptor-mediated endocytosis (ActRIIA/IIB internalization), binding to circulating antagonists (follistatin, FSTL3, GASP-1/2), and hepatic clearance.
- Distribution
- GDF-11 mRNA is broadly expressed in brain, spleen, kidney, pancreas, heart, and skeletal muscle. Circulating levels reflect contributions from multiple tissues.
- Oral
- Not orally bioavailable. Requires parenteral administration. Recombinant protein is typically delivered IP or IV in research settings.
Quick Start
- Route
- Intraperitoneal or intravenous injection (research)
Research Indications
Rejuvenation
Landmark 2013 Cell study showed exogenous GDF11 reverses age-associated cardiac hypertrophy in mice. GDF11 levels decline with age and supplementation restores youthful cardiac structure.
Chronic GDF11 administration enhances cognitive abilities, restores neural activity, and promotes hippocampal neurogenesis while reducing neuroinflammatory markers in aged mice.
GDF11 supplementation reversed functional impairments in aged muscle stem cells, improved muscle structural features, and increased strength and endurance capacity. Some contradictory studies exist.
GDF11 attenuates the association between higher amyloid burden and worse cognition in cognitively unimpaired older adults, suggesting brain resilience support. Translational evidence warrants further study.
Research Protocols
intravenous Injection
- Routes: Intraperitoneal (most common in mice), intravenous.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Muscle wasting | 0.1 mg | Per protocol | — |
| Dosing (preclinical) | 0.1 mg | Per protocol | 30 days |
intraperitoneal Injection
- Routes: Intraperitoneal (most common in mice), intravenous.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Aged mice | 0.1 mg | Per protocol | 30 days |
Interactions
Peptide Interactions
GDF-11's pro-neurogenic effects in the SVZ may complement BDNF-TrkB-mediated synaptic plasticity. GDF-11 promotes neural stem cell proliferation and differentiation while BDNF supports neuronal survival and synaptic integration of newly born neurons.
Both are circulating factors implicated in aging. Klotho targets the insulin/IGF-1 and Wnt pathways while GDF-11 acts through Smad2/3. Their combined effects on cardiac and brain aging represent a complementary multi-target approach to rejuvenation research.
Follistatin is a natural GDF-11/GDF-8 antagonist. Follistatin gene therapy (Follistatin-344 overexpression) enhances muscle mass by blocking both factors. Follistatin-315 is the related peptide page.
What to Expect
What to Expect
GDF-11 knockout mice die within 24 hours of birth due to renal agenesis, cleft palate, and skeletal abnormalities including extra vertebrae and ribs.
Duration: Cardiac studies: 28-30 days.
Continued use as directed
Safety Profile
Common Side Effects
- Anemia Risk:: Excessive natural levels or over-expression can lead to suppressed red blood cell counts.
- Oncogenic Potential:: Upregulation is linked to poor outcomes in certain malignant conditions.
- Erythrocytosis:: In therapeutic contexts, blocking GDF-11 can lead to abnormally high red blood cell or platelet counts.
Quality Indicators
What to look for
- Human clinical trials conducted
- Extensive peer-reviewed research base
Caution
- Limited human data available
Frequently Asked Questions
References (22)
- [8]Ge G, Hopkins DR, Ho WB, Bhd Greenspan DS GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells Mol Cell Biol (2005)
- [9]Sako D, Grinberg AV, Liu J, et al Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb J Biol Chem (2010)
- [14]Schafer MJ, Atkinson EJ, Vanderboom PM, et al Quantification of GDF11 and myostatin in human aging and cardiovascular disease Cell Metab (2016)
- [20]Schafer et al — GDF11 and its emerging roles beyond development: implications for cardiovascular and neurological function Cytokine Growth Factor Rev (2023)
- [22]
- [10]Loffredo FS, Steinhauser ML, Jay SM, et al Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy Cell (2013)
- [11]Katsimpardi L, Litterman NK, Schein PA, et al Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors Science (2014)
- [12]Sinha M, Jang YC, Oh J, et al Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle Science (2014)
- [13]Egerman MA, Cadena SM, Gilbert JA, et al GDF11 increases with age and inhibits skeletal muscle regeneration Cell Metab (2015)
- [15]Walker RG, Poggioli T, Katsimpardi L, et al Biochemistry and biology of GDF11 and myostatin: similarities, differences, and questions for future investigation Circ Res (2016)
- [16]Walker RG, McCoy JC, Czepnik M, et al Molecular characterization of latent GDF8 reveals mechanisms of activation Proc Natl Acad Sci USA (2017)
- [17]Harmon EB, Apelqvist AA, Smart NG, et al GDF11 modulates NGN3+ islet progenitor cell number and promotes beta-cell differentiation in pancreas development Development (2004)
- [18]Suragani RNVS, Cadena SM, Cawley SM, et al Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis Nat Med (2014)
- [19]Harper RL, et al Sotatercept for the treatment of pulmonary arterial hypertension N Engl J Med (2024)
- [21]Li et al — Growth differentiation factor 11 promotes neurovascular recovery after stroke in mice Nat Commun (2023)
- [7]Nakashima M, Toyono T, Akamine A, Joyner A Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis Mech Dev (1999)
- [1]Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
→ This review identifies GDF-11 as a negative regulator of terminal erythroid differentiation and explores how trapping this ligand can treat anemia in myelodysplastic syndromes.
- [2]Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial
→ Clinical study showing that inhibiting GDF-11 and related ligands can safely increase the production of red blood cells and platelets in humans.
- [3]GDF11 is increased in patients with aplastic anemia
→ Research findings show that high levels of GDF-11 are significantly correlated with impaired red blood cell production in patients with aplastic anemia.
- [4]Lifelong exercise, but not short-term high-intensity interval training, increases GDF11, a marker of successful aging
→ Preliminary evidence suggesting that GDF-11 levels are higher in older men who have maintained lifelong exercise habits compared to sedentary peers.
- [5]Age Trends in Growth and Differentiation Factor-11 and Myostatin Levels in Healthy Men
→ A study using advanced mass spectrometry to clarify the relationship between GDF-11, aging, and muscle growth regulators in healthy males.
- [6]McPherron AC, Lawler AM, Lee SJ Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11 Nat Genet (1999)
Galanin
Galanin is a 29-amino acid neuropeptide (30 in most non-human species) that signals through GalR1, GalR2, and GalR3 receptor subtypes to modulate depression, pain, cognition, feeding behavior, and seizure activity. GalR2 agonists are emerging as novel antidepressant candidates, while galanin's role in Alzheimer's disease through regulation of basal forebrain cholinergic neurons makes it a key target in neurodegeneration research.
Growth Differentiation Factor 9 (GDF-9)
GDF-9 is a TGF-β superfamily member secreted exclusively by oocytes that regulates cumulus cell expansion, granulosa cell proliferation, and folliculogenesis. It serves as a biomarker for oocyte quality in IVF and is implicated in PCOS follicular dysregulation, premature ovarian insufficiency, and twin ovulation rate genetics.